Ohmyhome, Webuy Forge Partnership To Elevate Property And E-Commerce Services In Singapore

Ohmyhome Ltd. (NASDAQ: OMH) and Webuy Global Ltd. (NASDAQ: WBUY) announce a strategic collaboration to 

Ohmyhome Ltd. (NASDAQ:OMH) and Webuy Global Ltd. (NASDAQ:WBUY) announce a strategic collaboration to cross-sell their distinct services in Singapore. 

Webuy will offer Ohmyhome’s property listing, renovation and other services through its community e-commerce platform and Group Leaders.

Group Leaders will play a crucial role in this integration, offering Ohmyhome’s property listings and services to their respective community members, thus facilitating unique off-market opportunities and exclusive perks.

Webuy will introduce its ‘group buy’ service to Ohmyhome’s homeowner base, providing an array of products from groceries to travel deals.

In line with Webuy’s Online-to-Offline (O2O) strategy, Ohmyhome will assist in establishing new retail fronts. This move is part of Webuy’s ambitious plan to open 100 stores across key Singaporean locales, a significant step in expanding their retail footprint.

Rhonda Wong, CEO and Co-founder of Ohmyhome, added, “This collaboration allows both companies to leverage on our respective broad customer bases, thereby increasing our reach and complementing each other’s service offerings centered around homes and communities.”

Price Action: OMH shares are trading higher by 1.32% to $1.54, and WBUY is up 0.95% at $0.53 on the last check Monday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Total
0
Shares
Related Posts
Read More

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data on symptom improvement and quality of life related to treatment with aficamten in REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM Open Label Extension) in a Late Breaking Clinical Trials session at the Heart Fa

CYTK